India has long been described as the “pharmacy of the world.” The title is well earned. The country supplies close to 20% of global generic medicines by volume and plays a central role in affordable healthcare across developed and emerging markets.
Its importance is especially visible in the United States. In 2022, Indian pharmaceutical companies supplied around 47% of all generic prescriptions dispensed in the U.S. market. In several major treatment areas, including hypertension, mental health, and lipid regulation, Indian firms supplied more than half of all prescriptions.
This makes India a critical pillar of global healthcare resilience. Yet the strength of India’s pharmaceutical export machine depends on a less visible input base. The finished medicines may be Indian. Much of the upstream chemistry is not.
The Tariff Shock India Avoided
In 2026, new U.S. tariffs on branded and patented pharmaceuticals created concern across the global drug industry. Indian generic manufacturers were largely spared in the immediate term because the duties focused on patented medicines, not the low-cost generics that dominate India’s export portfolio.
This gave Indian drugmakers short-term protection. It also reinforced India’s position as a cost-efficient supplier of essential medicines to the U.S., the U.K., and many countries in the Global South.
However, tariff protection does not remove supply chain risk. India may be relatively protected from one trade policy shock, but it remains highly exposed to upstream dependence on China.
The API Dependency Problem
India imports a large share of its active pharmaceutical ingredients, key starting materials, and intermediates from China. Estimates vary by category, but the dependency remains structurally high. China accounts for around 40% of global API output, while Indian producers source roughly two-thirds or more of critical pharma inputs from Chinese suppliers.
For some essential medicines, the exposure is even sharper. Inputs for products such as paracetamol, penicillin, and ibuprofen have import dependency levels that can exceed 90%. This creates a strategic vulnerability in a sector where continuity matters not only for business performance, but also for public health.
China’s advantage is not accidental. It reflects large-scale production, lower energy costs, integrated chemical clusters, established effluent treatment capacity, and long-term state support. Rebuilding such an ecosystem elsewhere requires time, capital, environmental infrastructure, and predictable demand.
A Transitive Risk for Western Markets
The most important point is that this is not only India’s problem. It is also a risk for the countries that depend on Indian generics.
The pharmaceutical supply chain is transitive. U.S. and U.K. patients rely on Indian formulations. Indian formulations rely on Chinese APIs and intermediates. As a result, Western healthcare systems inherit part of India’s upstream exposure.
A disruption at one node can move through the entire chain. If Chinese exports of critical pharmaceutical inputs were restricted, delayed, or made more expensive, the impact would not stop at Indian factories. It could affect the availability and cost of generic medicines in pharmacies, hospitals, and public healthcare systems abroad.
This risk is not theoretical. Recent disruptions in freight routes, energy prices, and petrochemical costs showed how quickly upstream pressure can affect pharmaceutical inputs. In 2026, Indian exporters warned of falling inventories of solvents and key starting materials, while some raw material costs reportedly rose by 20% to 30% before supplies stabilized.
India’s Policy Response Is Real, But Still Partial
New Delhi has started to address the issue. The Production-Linked Incentive scheme for bulk drugs has supported domestic manufacturing of critical products. India has also restarted production of penicillin G and related molecules after more than two decades.
This is a meaningful step. Yet it is not enough to rebuild an industrial base that weakened over 20 years. Incentives can support capacity, but they do not automatically create full supply chain substitution. Domestic production must become cost-competitive, environmentally viable, and integrated into downstream demand.
There is also another challenge. Higher Indian API output may support exports rather than reduce domestic dependence on Chinese inputs. For self-reliance to improve, new capacity must be aligned with India’s own pharmaceutical manufacturing needs and with the resilience priorities of partner markets.
A Strategic Opportunity for India and Its Partners
India’s API challenge should be treated as a shared economic security issue. For Western partners, financing India’s upstream pharmaceutical capacity is not charity. It is a practical investment in their own medicine security.
Co-investment in bulk drug parks, joint qualification of non-Chinese suppliers, shared stockpiles of essential intermediates, and harmonized conformity standards could reduce systemic risk. These measures would turn a private cost for Indian manufacturers into a public good for global healthcare systems.
The same logic applies beyond pharmaceuticals. Critical minerals, solar modules, and batteries all show how midstream economies can become strategic nodes. If those nodes remain dependent on China for key inputs, the dependence is passed through to every downstream partner.
India’s recent trade diplomacy creates room for a broader bargain. The EU-India Free Trade Agreement, deeper trade engagement with the United States, and India’s National Critical Minerals Mission all point in the same direction: resilience now belongs at the centre of economic partnerships.
The strategic narrative should move beyond “India as an alternative to China.” A more accurate view is “India as a load-bearing node in global supply chains.” Its strengths are valuable. Its vulnerabilities are shared.
For India, reducing dependence on imported strategic inputs is not narrow industrial policy. It is a contribution to allied supply chain security. For its partners, the lesson is clear: routing supply through India does not remove China risk if India’s upstream chemistry remains tied to China.
A tariff wall can protect a market from some finished products. It cannot protect the global economy from the chemistry inside them.